

## DAFTAR PUSTAKA

- Adriana Olar, Khalida M Wani, Erik P Sulman, Alireza Mansouri, Gelareh Zadeh, et al. 2015; Mitotic index is an independent predictor of recurrence free survival in meningioma. *Brain Pathol.* 25(3): 266–275
- Amit Deshpande, Peter Sicinski and Philip W Hinds. 2005 Cyclins and cdks in development and cancer: a perspective. *Oncogene* (2005) 24, 2909–2915
- An HX, Beckmann MW, Reifemberger G, Bender HG and Niederacher D. 1999. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. *Am. J. Pathol.*, 154, 113–118.
- Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM *et al.* 2011. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. *Cancer Cell* 2011; 20: 620–634
- Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. 2004. p27Kip1 modulates cell migration through the regulation of RhoA activation. *Genes Dev.* 2004;18:862-76
- Blazek D, Kohoutek J, Bartholomeeusen K, et al. 2011. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. *Genes Dev.* 2011;25:2158-72
- Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H and Ingvar C. (2000). High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. *J. Natl. Cancer Inst.*, 92, 1260–1266
- Brown N, Korolchuk S, Martin M, Stanley W, Moukhametzianov R, Noble M, et al. 2014. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK. *Nature Communications* 2014; 6(6769):
- Burd CE, Sorrentino JA, Clark KS, Darr DB, Krishnamurthy J, Deal AM, et al. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. *Cell.* 2013 Jan 17;152(1–2):340–51
- Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, & Aksoy BA, 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2:401–404, 2012. (Erratum in *Cancer Discov* 2:960, 2012)

- Charles J. Sherr and James M. Roberts. 1999. CDK inhibitors: positive and negative regulators of G<sub>1</sub>-phase progression. *Genes & Dev.* 1999. 13: 1501-1512
- Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I. 2011. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurg Focus.* 2011;30:E6.
- Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL *et al.* 2012. The requirement for cyclin D function in tumor maintenance. *Cancer Cell* 2012; 22: 438–451.
- Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. 2006. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. *Nature.* 2006 Sep 14;443(7108):214–7
- Claus EB, Black PM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL, Wrensch M. 2007. Exogenous hormone use and meningioma risk: what do we tell our patients? *Cancer.* 2007;110:471–476. doi: 10.1002/cncr.22783.
- Daniel J Wood, & Jane A Endicott. 2018. Structural insights into the functional diversity of the CDK-cyclin family. 2018 *Open Biol.* Sep;8(9):180112. doi: 10.1098/rsob.180112.
- David Santamaría , Cédric Barrière, Antonio Cerqueira, Sarah Hunt, Claudine Tardy, Kathryn Newton, Javier F Cáceres, Pierre Dubus, Marcos Malumbres, Mariano Barbacid. 2007. Cdk1 is sufficient to drive the mammalian cell cycle. *Nature.* 2007 Aug 16;448(7155):811-5. doi: 10.1038/nature06046.
- David N. Louis, Arie Perry, Pieter Wesseling , Daniel J. Brat , Ian A. Cree, Dominique Figarella-Branger, Cynthia Hawkins, H. K. Ng, Stefan M. Pfister, Guido Reifenberger, Riccardo Soffietti, Andreas von Deimling, and David W. Ellison. 2021. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro-Oncology* XX(XX), 1–21, 2021 | doi:10.1093/neuonc/noab106
- Deborah L. Commins, R. Atkinson, and M. E. Burnett. 2007. Review of meningioma histopathology. *Neurosurg Focus* 23 (4):E3.
- Domingues, P. et al. (2015) 'Genetic Molecular Alterations of Meningiomas and the Signaling Pathways Targeted', *Oncotarget*, 6(13), pp. 10671–10688. doi: 10.18632/oncotarget.3870.

- Elizabet E. Claus & Alan L. Morison. 2011. Epidemiologi Meningioma In: In: Al Mefty Meningiomas. Thieme. Newyork. P. 401-420
- Erik S. Knudsen and Agnieszka K. Witkiewicz. 2017. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer. 2017 January ; 3(1): 39–55. doi:10.1016/j.trecan.2016.11.006
- Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. 2016. Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine. 2016;375(20):1925-36.
- Foster David A., Paige Yellen, Limei Xu, and Mahesh Saqcena. 2011. Regulation of G1 Cell Cycle Progression, Genes Cancer. 2010 Nov; 1(11): 1124–1131.
- Freed G Barker, Patrick J. Cod, William T. Curry, 2011.Meningioma Surgery: Experience, volume of care and patients outcome, In: Al Mefty Meningiomas. Thieme. Newyork. P. 401-420
- García-Reyes B., Kretz A.L., Ruff J.P., von Karstedt S., Hillenbrand A., Knippschild U., Henne-Bruns D., Lemke J. 2018. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int. J. Mol. Sci. 2018;19:3219. doi: 10.3390/ijms19103219.
- Giulia Cossu, Mahmoud Messerer, Fabrice Parker, Marc Levivier and Roy Thomas Daniel. 2016. Meningiomas' Management: An Update of the Literature. Neurooncology - Newer Development. Chapter 15. P.361-385. <http://dx.doi.org/10.5772/62929>
- Goldbrunner, R. et al. 2016 'Review EANO Guidelines for the Diagnosis and Treatment of Meningiomas', Lancet Oncology. Elsevier Ltd, 17(9), pp. e383–e391. doi: 10.1016/S1470-2045(16)30321-7
- Gong X , Lacey M Litchfield , Yue Webster , Li-Chun Chio , Swee Seong Wong , et. al. 2017. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer Cell. 2017.Dec 11;32(6):761-776.e6. doi: 10.1016/j.ccell. 2017.11.006.
- Hanahan D, & Weinberg RA, 2011. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4; 144(5):646-74.
- Hara M, Abe Y, Tanaka T, Yamamoto T, Okumura E, Kishimoto T. Greatwall kinase and cyclin B-Cdk1 are both critical constituents of M-phase-promoting factor. Nat Commun. 2012;3:1059

- Hassan KA, Ang K, El-Naggar AK, et al. 2002. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. *Cancer Res.* 2002;62:6414-7
- Helfrid Hochegger, Donniphat Dejsuphong, Eiichiro Sonoda, Alihossein Saberi, Eeson Rajendra, J ane Kirk, Tim Hunt, and Shunichi Takeda. 2007. An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. *J Cell Biol.* 2007 Jul 16; 178(2): 257–268. doi: 10.1083/jcb.200702034
- J Xuereb and R. Blundell, 2008. The Role of Cell Cycle Regulation in Cancer, *Research Journal of Biological Sciences* 3 (2): 251-257
- Johnson M, & Toms S. 2005. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? *J NeuropatholExp Neurol.* 2005;64:1029–1036.
- Johnson N & Shapiro GI. 2010. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. *Expert OpinTherTargets.* 2010; 14:1199-212
- Kawamoto H, Koizumi H, Uchikoshi T. 1997. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. *Am J Pathol.* 1997;150:15-23
- Kevin J. Barnum and Matthew J. O’Connell, 2014, Cell Cycle Regulation by Checkpoints, *Methods Mol Biol.* 2014 ; 1170: 29–40
- Kopper F, Bierwirth C, Schon M, Kunze M, Elvers I, Kranz D, et al. 2013. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. *ProcNatlAcadSci U S A.* 2013 Oct 15;110(42):16856–61.
- Konstantinos Gousias, Johannes Schramm, and Matthias Simon, 2016. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management. *J Neurosurg* 125:551–560.
- Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. 2006 Association of meningioma with reproductive factors. *Int J Cancer.* 2006;119:1152–1157. doi: 10.1002/ijc.21950.
- Lim S, & Kaldis P. 2013. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. *Development* 2013; 140(15): 3079-3093.

- Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S *et al.* 2004. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. *Cell* 2004; 118: 493–504.
- Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer*. 2009;9:153–66.
- Malumbres M, 2014. Cyclin-dependent kinases. *Genome Biol*. 2014; 15(6):122.
- Mary E. Law, Patrick E. Corsino, Satya Narayan, and Brian K. Law. 2015. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. *Mol Pharmacol*. 2015 Nov. 88(5); 846-852.
- Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, Pambor C, Vorwerk CK, Firsching R, Lendeckel U, Dietzmann K. 2005. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. *Clin Cancer Res*. 2005;11:4074–4082.
- Miller Jr, R. *et al.* 2014 'Molecular Targets and Treatment of Meningioma', *Journal of Neurology and Neurosurgery*, 1(1)(1000101), pp. 1–7. doi: <http://dx.doi.org/10.19104/jnn.2014.101>.
- Miyata Y, Liu Y, Jankovic V, *et al.* 2010. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. *Stem Cells*. 2010;28:308-17
- Mochida S, Ikeo S, Gannon J, Hunt T. 2009. Regulated activity of PP2A-B55 delta is crucial for controlling entry into and exit from mitosis in *Xenopus* egg extracts. *EMBO J*. 2009;28:2777-85
- Molinari, M . 2000. Cell cycle checkpoints and their inactivation in human cancer, *Cell Prolif*. 2000 Oct; 33(5): 261–274.
- Neganova I., Tilgner K., Buskin A., Paraskevopoulou I., Atkinson S.P., Peberdy D., Passos J.F., Lako M. 2014. CDK1 plays an important role in the maintenance of pluripotency and genomic stability in human pluripotent stem cells. *Cell Death Dis*. 2014;5:1508. doi: 10.1038/cddis.2014.464
- Nicholas R. Brown, Svitlana Korolchuk, Mathew P. Martin, Will A. Stanley, Rouslan Moukhametzianov, Martin E.M. Noble & Jane A. Endicott. 2015. CDK1 structures reveal conserved and unique features of the essential cell cycle CDK, *Nature communications* 6, Article number: 6769 (2015)
- Nigg E.A. 2001. Mitotic Kinases as Regulators of Cell Division and its Checkpoints. *Nat. Rev. Mol. Cell Biol*. 2001;2:21–32. doi: 10.1038/35048096.

- Nurse P. 2000. A long twentieth century of the cell cycle and beyond. *Cell*. 2000 Jan 7; 100(1):71-8.
- Onder Us dan Dilaver Kaya, 2010 Clinical Presentation of Meningioma in meningiomas, Saunders; Philadelphia, 1<sup>st</sup>.Ed. p.165
- Osborn, Anne G., James G. Smirniotopoulos, David A. Clunie, John Howieson, and A. N. D 'Agostino. 1992. Radiologic-Pathologic Correlation Intracranial .Meningioma Lori A. Sheporaitis. *AJNR*: 13, January/February 1992
- Ostrom, Quinn T, Haley Gittleman, JordonnaFulop R.N, Max Liu, Rachel Blanda, et.all. 2015. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. *Neuro-Oncology* 17:iv1–iv62
- Ostrom, Q.T.; Cioffi, G.; Gittleman, H.; Patil, N.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: 2019. Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. *Neuro Oncol*. 2019, 21, v1–v100
- Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A, Kirches E, Mawrin C. 2013. mTORC1 inhibitors suppress meningioma growth in mouse models. *Clin Cancer Res*. 2013;19:1180–1189
- Perry, A., Louis, D. N., Budka, H., von Deimling, A., Sahm, F., Mawrin, C., et al. 2016 'Meningioma Variants', in Louis, D. N. et al. (eds) *WHO Classification of Tumours of the Central Nervous System*. Revised 4th edn. Lyon: International Agency for Research on Cancer (IARC), pp. 237–245.
- Phillips LE, Koepsell TD, Belle G, Kukull WA, Gehrels JA, Longstreth WT., Jr. 2002. History of head trauma and risk of intracranial meningioma: population-based case–control study. *Neurology*. 2002;58:1849–1852.
- Raj K. Shrivastava, Salomao Segal, Martin B. Camins , Chandranathn Sen and Kalmon D. Post. 2003. Harvey Cushing's *Meningiomas* text and the historical origin of resectability criteria for the anterior one third of the superior sagittal sinus. *Journal of Neurosurgery*. Volume 99: Issue 4 (Oct 2003)
- Riemenschneider MJ, Perry A, Reifenberger G. 2006. Histological classification and molecular genetics of meningiomas *The Lancet Neurology*, volume 5, p.1045–54

- Rosa Wijnen, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J. Peters, Elisa Giovannetti, and Patrizia Diana. 2021. Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC) *Cancers* 2021, 13, 4389. <https://doi.org/10.3390/cancers13174389>
- Sadetzki S, Flint-Richter P, Starinsky S, Novikov I, Lerman Y, et.al. 2005. Genotyping of patients with sporadic and radiation-associated meningiomas. *Cancer Epidemiol Biomarkers Prev.* 2005;14:969–976.
- Sanja M Milenkovic, Tatjana Marinkovic, Milan B Jovanovic, & Slavisa M Djuricic. 2008. Cyclin D1 Immunoreactivity in Meningiomas, *Cellular and Molecular Neurobiology* 28(6):907-13
- Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J. Lord, and Alan Ashworth. 2016. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. *PLoS One.* 2016; 11(2): e0149099
- Sherr CJ . 2000. The Pezcoller lecture: cancer cell cycles revisited. *Cancer Res;* 60: 3689–3695.
- Shom Goel , Molly J DeCristo , Sandra S McAllister , Jean J Zhao, 2018. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. *Trends Cell Biol.* 2018 Nov;28(11):911-925. doi: 10.1016/j.tcb.2018.07.002. Epub 2018 Jul 27.
- Soria JC, Jang SJ, Khuri FR, et al. 2000. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. *Cancer Res.* 2000;60:4000-4
- Suzuki T, Urano T, Miki Y, et al. 2007. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. *Cancer Sci.* 2007;98:644-51
- Thomas DM, Yang HS, Alexander K and Hinds PW. 2003. Role of *the* retinoblastoma protein in differentiation and senescence. *Cancer Biol. Ther.*, 2, 124–130.
- Tobias Otto & Piotr Sicinski, 2017. Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer.* 2017 Jan 27;17(2):93-115. doi: 10.1038/nrc.2016.138.
- Uzma Asghar, Agnieszka K. Witkiewicz, Nicholas C. Turner, and Erik S. Knudsen, 2015. The history and future of targeting cyclin-dependent kinases in cancer therapy, *Nat Rev Drug Discov.* 2015 February ; 14(2): 130–146
- Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. 1977. Overexpression of cyclin B1 in human colorectal cancers. *J Cancer Res Clin Oncol.* 1997;123:124-7

- Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH and Ladanyi M. 1999. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. *Int. J. Cancer*, 80, 199–204
- Wiemels, Joseph, Margaret Wrensch, Elizabeth B. Claus. 2010. Epidemiology and etiology of meningioma. *J Neurooncol.* 99:307–314
- Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, Lichter P. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. *Int J Cancer.* 2005;114:249–256.
- Y J Choi & L Anders. 2014. Signaling through cyclin D-dependent kinases *Oncogene* volume 33, pages 1890–1903
- Yigal Shoshan, Sergey Spektor, Guy Rosenthal, Shifra Fraifeld, and Felix Umansky. 2009. Radiation-Induced Meningioma: Historical Perspective, Presentation, Management, and Genetics. *Meningiomas* pp 163-176
- Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA, Hanemann CO. 2010. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. *Neoplasia.* 2010;13:1101–1112.
- Vielba R, Bilbao J, Ispizua A, Zabalza I, Alfaro J, Rezola R, Moreno E, Elorriaga J, Alonso I, Baroja A and de la Hoz C. (2003). p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. *Laryngoscope*, 113, 167–172



## Data Hasil Penelitian

No	Sampel	JK	Umur	Grade	Tipe histopatologi	Mitosis	Cdk 1	Cdk 4	Cyclin B
1	S1	L	45	2	Atypical Meningioma	3-5	0.01924	0.00133	0.00141
2	S10	P	48	1	Meningothelial Meningioma	0	0.01178	0.00195	0.00088
3	S101	L	54	2	Chordoid Meningioma	6	0.04119	0.02776	0.00416
4	S102	P	51	3	Anaplastic meningioma	>20	0.07596	0.13286	0.02124
5	S103	P	49	1	Fibroblastic Meningioma	1	0.01944	0.01465	0.00119
6	S104	P	42	3	Anaplastic meningioma	>20	0.00798	0.00856	0.00133
7	S105	P	52	3	Papillary Meningioma	>20	0.48257	0.84081	0.36599
8	S106	P	56	3	Anaplastic meningioma	>20	0.02789	0.29312	0.02060
9	S107	P	57	2	Atypical Meningioma	10	0.03075	0.01382	0.03532
10	S108	P	54	1	Meningothelial Meningioma	2	0.01509	0.01497	0.00000
11	S109	P	68	2	Atypical Meningioma	2-4	0.00993	0.11632	0.00145
12	S11	P	46	3	Anaplastic meningioma	>20	0.07159	0.04620	0.00931
13	S111	P	65	3	Papillary Meningioma	0	0.05092	0.19485	0.04488
14	S2	L	62	1	Mycrocystic Meningioma	0	0.00643	0.00173	0.00081
15	S21	P	54	1	Meningothelial Meningioma	0	0.00792	0.00424	0.00126
16	S22	P	44	3	Anaplastic meningioma	3	0.00437	0.01386	0.00529
17	S23	P	61	1	Fibroblastic Meningioma	1	0.00673	0.00098	0.00475
18	S25	P	49	3	Anaplastic meningioma	20	0.01613	0.13460	0.00568
19	S26	P	41	2	Atypical Meningioma	6	0.01605	0.00580	0.00264
20	S27	P	38	2	Atypical Meningioma	0	0.01249	0.00160	0.00007
21	S28	P	45	1	Meningothelial Meningioma	2	0.00053	0.00139	0.00000
22	S29	L	40	1	Mixed Meningioma	1	0.00335	0.00000	0.00064
23	S3	L	48	2	Atypical Meningioma	6	0.00228	0.00017	0.00106
24	S30	P	52	1	Mixed Meningioma	2	0.00001	0.00000	0.00094
25	S31	P	55	3	Anaplastic meningioma	20	0.00284	0.03082	0.00514
26	S32	L	53	3	Anaplastic meningioma	3	0.04975	0.00164	0.00607
27	S33	L	50	3	Anaplastic meningioma	10-15	0.06345	0.00146	0.01061
28	S34	P	46	3	Papillary Meningioma	25	0.03243	0.01865	0.04257
29	S35	P	54	1	Psammomatous Meningioma	0	0.00038	0.00045	0.00041
30	S36	P	61	1	Fibroblastic Meningioma	0	0.00219	0.00094	0.00058

No	Sampel	JK	Umur	Grade	Tipe histopatologi	Mitosis	Cdk 1	Cdk 4	Cyclin B
31	S37	P	55	3	Anaplastic meningioma	20-25	0.00852	0.01529	0.01101
32	S38	P	64	1	Mycrocystic Meningioma	3	0.00050	0.00441	0.00964
33	S39	P	63	2	Chordoid Meningioma	0	0.02465	0.05801	0.00141
34	S4	P	47	2	Atypical Meningioma	4	0.01560	0.00180	0.00055
35	S40	P	50	2	Atypical Meningioma	6	0.00079	0.00929	0.02112
36	S41	P	68	1	Meningothelial Meningioma	1	0.00147	0.00482	0.00092
37	S42	L	51	3	Anaplastic meningioma	20	0.00653	0.00691	0.00266
38	S43	P	66	2	Atypical Meningioma	0	0.01314	0.09100	0.00081
39	S44	P	46	2	Atypical Meningioma	10	0.01495	0.00728	0.00106
40	S45	L	54	1	Fibroblastic Meningioma	0	0.00732	0.01017	0.00642
41	S46	L	48	3	Anaplastic meningioma	25	0.00312	0.00017	0.00225
42	S47	P	49	2	Chordoid Meningioma	3	0.00127	0.00035	0.00024
43	S48	P	53	2	Atypical Meningioma	10	0.01895	0.00021	0.00028
44	S49	L	62	3	Anaplastic meningioma	>20	0.05168	0.00191	0.00473
45	S5	L	51	1	Transisional Meningioma	0	0.00000	0.00055	0.00014
46	S50	P	41	1	Transisional Meningioma	0	0.00771	0.00646	0.00511
47	S51	P	48	2	Atypical Meningioma	4-6	0.01143	0.00825	0.00788
48	S52	P	63	1	Meningothelial Meningioma	1	0.00091	0.00156	0.00023
49	S53	L	50	2	Atypical Meningioma	6	0.00247	0.01198	0.00027
50	S54	P	56	1	Transisional Meningioma	1	0.00389	0.00243	0.00009
51	S55	L	50	3	Anaplastic meningioma	20	0.01589	0.00167	0.00577
52	S56	L	61	3	Anaplastic meningioma	>20	0.03756	0.01017	0.00644
53	S57	P	46	1	Transisional Meningioma	3	0.00078	0.01122	0.01764
54	S58	P	48	2	Atypical Meningioma	10	0.00173	0.04033	0.02217
55	S59	P	52	2	Chordoid Meningioma	8	0.00382	0.08613	0.07120
56	S6	P	56	2	Atypical Meningioma	0	0.01933	0.00409	0.00441
57	S60	L	48	2	Atypical Meningioma	3-5	0.00127	0.04282	0.06003
58	S61	P	39	2	Atypical Meningioma	10-15	0.01480	0.05190	0.07154
59	S62	L	53	3	Papillary Meningioma	<10	0.00116	0.00516	0.04074
60	S63	L	48	1	Mixed Meningioma	0	0.00719	0.01961	0.00055
61	S64	P	44	2	Chordoid Meningioma	8	0.00462	0.00942	0.00014
62	S65	L	47	3	Anaplastic meningioma	25	0.02392	0.10359	0.11311

No	Sampel	JK	Umur	Grade	Tipe histopatologi	Mitosis	Cdk 1	Cdk 4	Cyclin B
63	S66	P	57	1	Psammomatous Meningioma	2	0.00003	0.00363	0.00010
64	S67	L	45	1	Meningothelial Meningioma	1	0.00001	0.00338	0.00009
65	S68	P	48	2	Atypical Meningioma	10	0.00025	0.00328	0.02440
66	S69	P	51	2	Chordoid Meningioma	8	0.02374	0.00885	0.00441
67	S7	P	49	3	Anaplastic meningioma	>20	0.00043	0.00166	0.00558
68	S70	P	70	1	Transisional Meningioma	1	0.01091	0.00532	0.00558
69	S72	P	57	3	Anaplastic meningioma	>25	0.00917	0.11998	0.10575
70	S73	L	62	2	Atypical Meningioma	10	0.01304	0.00154	0.07249
71	S74	P	60	2	Chordoid Meningioma	10	0.00181	0.01646	0.03189
72	S75	P	51	2	Atypical Meningioma	15	0.01095	0.00784	0.00012
73	S76	L	52	1	Mixed Meningioma	1	0.00010	0.00089	0.00088
74	S77	P	68	1	Psammomatous Meningioma	2	0.01033	0.00052	0.00931
75	S78	P	58	1	Psammomatous Meningioma	0	0.00457	0.01516	0.06032
76	S79	P	54	2	Atypical Meningioma	5-10	0.00938	0.13464	0.00126
77	S8	P	56	2	Atypical Meningioma	10	0.00563	0.19135	0.07249
78	S80	P	49	1	Fibroblastic Meningioma	1	0.00008	0.00401	0.00000
79	S81	P	49	1	Meningothelial Meningioma	1	0.00001	0.00468	0.00003
80	S82	P	49	2	Atypical Meningioma	5-10	0.00317	0.00772	0.00529
81	S83	L	52	2	Chordoid Meningioma	5	0.01754	0.00000	0.00475
82	S86	P	55	1	Mixed Meningioma	0	0.00045	0.00443	0.01108
83	S87	L	39	3	Papillary Meningioma	>20	0.00195	0.00779	0.00568
84	S88	P	62	1	Fibroblastic Meningioma	2	0.00112	0.00053	0.00264
85	S89	P	60	3	Anaplastic meningioma	3	0.11064	0.01857	0.00694
86	S9	P	54	1	Transisional Meningioma	0	0.00648	0.00045	0.00012
87	S91	P	54	3	Anaplastic meningioma	>25	0.03780	0.00074	0.00671
88	S92	P	48	3	Papillary Meningioma	20	0.00167	0.00698	0.00435
89	S93	L	51	2	Chordoid Meningioma	3	0.00195	0.00029	0.00094
90	S94	P	56	1	Psammomatous Meningioma	0	0.00000	0.00378	0.00000
91	S95	P	49	1	Meningothelial Meningioma	0	0.00018	0.00232	0.00868
92	S96	L	45	1	Mycrocystic Meningioma	1	0.00011	0.00823	0.00197
93	S97	L	48	2	Atypical Meningioma	5	0.02251	0.58788	0.02662
94	S98	P	66	1	Psammomatous Meningioma	1	0.01709	0.01735	0.00256
95	S99	P	48	2	Atypical Meningioma	>10	0.03966	0.48234	0.04484

## HASIL ANALISA SPSS

### Descriptives

Grade		Statistic	Std. Error	
CDK1	1	Mean	.0044311	
		95% Confidence Interval for Mean		
		Lower Bound	.0025786	
		Upper Bound	.0062837	
		5% Trimmed Mean	.0038994	
		Median	.0014700	
		Std. Deviation	.00539301	
		Minimum	.00000	
		Maximum	.01944	
		Range	.01944	
		Interquartile Range	.00721	
		Skewness	1.271	.398
		Kurtosis	.902	.778
		Mean	.0126582	.00184952
	2	95% Confidence Interval for Mean		
		Lower Bound	.0088954	
		Upper Bound	.0164211	
		Mean	.0117851	
		5% Trimmed Mean		
		Median	.0119600	
		Std. Deviation	.01078445	
		Minimum	.00025	
		Maximum	.04119	
		Range	.04094	
		Interquartile Range	.01660	
		Skewness	.999	.403
		Kurtosis	.777	.788
		Mean	.0459969	.01834826
	3	95% Confidence Interval for Mean		
		Lower Bound	.0082080	
		Upper Bound	.0837859	
		5% Trimmed Mean		
		95% Confidence Interval for Mean	.0290333	
		Mean	.0200250	
		5% Trimmed Mean		
		Median		
		Variance	.009	

		Std. Deviation	.09355812	
		Minimum	.00043	
		Maximum	.48257	
		Range	.48214	
		Interquartile Range	.04705	
		Skewness	4.373	.456
		Kurtosis	20.759	.887
		Mean	.0050631	.00092011
		95% Confidence Interval for Mean	Lower Bound	.0031932
CDK4	1	95% Confidence Interval for Mean	Upper Bound	.0069330
		5% Trimmed Mean		
		95% Confidence Interval for	.0045901	
		Mean	.0036300	
		5% Trimmed Mean		
		Median		
		Variance	.000	
		Std. Deviation	.00544347	
		Minimum	.00000	
		Maximum	.01961	
		Range	.01961	
		Interquartile Range	.00552	
		Skewness	1.365	.398
		Kurtosis	.844	.778
		Mean	.0597603	.02218591
		95% Confidence Interval for Mean	Lower Bound	.0146227
	2	95% Confidence Interval for Mean	Upper Bound	.1048979
		5% Trimmed Mean		
		95% Confidence Interval for	.0361508	
		Mean	.0090700	
		5% Trimmed Mean		
		Median		
		Variance	.017	
		Std. Deviation	.12936500	
		Minimum	.00000	
		Maximum	.58788	
		Range	.58788	
		Interquartile Range	.05168	
		Skewness	3.302	.403

		Kurtosis	11.013	.788
		Mean	.0776162	.03373401
		95% Confidence Interval for Mean	Lower Bound	.0081397
3		95% Confidence Interval for Mean	Upper Bound	.1470927
		5% Trimmed Mean		
		95% Confidence Interval for	.0465334	
		Mean	.0120150	
		5% Trimmed Mean		
		Median		
		Variance	.030	
		Std. Deviation	.17201039	
		Minimum	.00017	
		Maximum	.84081	
		Range	.84064	
		Interquartile Range	.10584	
		Skewness	3.835	.456
		Kurtosis	16.481	.887
		Mean	.0044446	.00178290
		95% Confidence Interval for Mean	Lower Bound	.0008213
Cyclin B	1	95% Confidence Interval for Mean	Upper Bound	.0080679
		5% Trimmed Mean		
		95% Confidence Interval for	.0026035	
		Mean	.0008800	
		5% Trimmed Mean		
		Median		
		Variance	.000	
		Std. Deviation	.01054778	
		Minimum	.00000	
		Maximum	.06032	
		Range	.06032	
		Interquartile Range	.00499	
		Skewness	4.676	.398
		Kurtosis	24.465	.778
		Mean	.0176094	.00427049
		95% Confidence Interval for Mean	Lower Bound	.0089210
2		95% Confidence Interval for Mean	Upper Bound	.0262978
		5% Trimmed Mean		
		95% Confidence Interval for	.0155338	

	Mean	.0042850		
	5% Trimmed Mean			
	Median			
	Variance		.001	
	Std. Deviation		.02490100	
	Minimum		.00007	
	Maximum		.07249	
	Range		.07242	
	Interquartile Range		.02703	
	Skewness		1.376	.403
	Kurtosis		.509	.788
	Mean		.0330935	.01449367
	95% Confidence Interval for Mean		Lower Bound	.0032432
3	95% Confidence Interval for Mean		Upper Bound	.0629437
	5% Trimmed Mean			
	95% Confidence Interval for	.0195941		
	Mean	.0065750		
	5% Trimmed Mean			
	Median			
	Variance		.005	
	Std. Deviation		.07390351	
	Minimum		.00133	
	Maximum		.36599	
	Range		.36466	
	Interquartile Range		.02086	
	Skewness		4.017	.456
	Kurtosis		17.681	.887





## Uji statistik perbedaan CSK1, CDK4, Cyclin B dengan Grade

### Kruskal-Wallis Test

Ranks			
	Grade	N	Mean Rank
CDK1	1	35	29.97
	2	34	53.96
	3	26	64.48
	Total	95	
CDK4	1	35	35.13
	2	34	53.57
	3	26	58.04
	Total	95	
Cyclin B	1	35	32.46
	2	34	50.51
	3	26	65.63
	Total	95	

Test Statistics <sup>a,b</sup>			
	CDK1	CDK4	Cyclin B
Kruskal-Wallis H	25.849	12.467	22.051
df	2	2	2
Asymp. Sig.	.000	.002	.000

a. Kruskal Wallis Test

b. Grouping Variable: Grade

### Median Test

		Grade		
		1	2	3
CDK1	> Median	8	21	18
	<= Median	27	13	8
CDK4	> Median	8	22	17
	<= Median	27	12	9
Cyclin B	> Median	10	15	22
	<= Median	25	19	4

### Test Statistics<sup>a</sup>

	CDK1	CDK4	Cyclin B
N	95	95	95
Median	.0073200	.0069100	.0044100
Chi-Square	16.034 <sup>b</sup>	15.708 <sup>b</sup>	19.352 <sup>b</sup>
df	2	2	2
Asymp. Sig.	.000	.000	.000

a. Grouping Variable: Grade

b. 0 cells (0.0%) have expected frequencies less than 5.  
The minimum expected cell frequency is 12.9.

## Analisis Post Hoc, Perbedaan rerata CDK1, CDK4, Cyclin B pada grade 1 dan 2

### Mann-Whitney Test

		Ranks		
	Grade	N	Mean Rank	Sum of Ranks
CDK1	1	35	25.54	894.00
	2	34	44.74	1521.00
	Total	69		
CDK4	1	35	28.49	997.00
	2	34	41.71	1418.00
	Total	69		
Cyclin B	1	35	28.46	996.00
	2	34	41.74	1419.00
	Total	69		

### Test Statistics<sup>a</sup>

	CDK1	CDK4	Cyclin B
Mann-Whitney U	264.000	367.000	366.000
Wilcoxon W	894.000	997.000	996.000
Z	-3.973	-2.737	-2.749
Asymp. Sig. (2-tailed)	.000	.006	.006

a. Grouping Variable: Grade

Analisis Post Hoc, Perbedaab rerata CDK1, CDK4, Cyclin B pada grade 1 dan 3  
**Mann-Whitney Test**

<b>Ranks</b>				
	Grade	N	Mean Rank	Sum of Ranks
CDK1	1	35	22.43	785.00
	3	26	42.54	1106.00
	Total	61		
CDK4	1	35	24.64	862.50
	3	26	39.56	1028.50
	Total	61		
Cyclin B	1	35	22.00	770.00
	3	26	43.12	1121.00
	Total	61		

<b>Test Statistics<sup>a</sup></b>			
	CDK1	CDK4	Cyclin B
Mann-Whitney U	155.000	232.500	140.000
Wilcoxon W	785.000	862.500	770.000
Z	-4.375	-3.245	-4.595
Asymp. Sig. (2-tailed)	.000	.001	.000

Analisis Post Hoc, Perbedaab rerata CDK1, CDK4, Cyclin B pada grade 2 dan 3  
**Mann-Whitney Test**

<b>Ranks</b>				
	Grade	N	Mean Rank	Sum of Ranks
CDK1	2	34	26.72	908.50
	3	26	35.44	921.50
	Total	60		
CDK4	2	34	29.37	998.50
	3	26	31.98	831.50
	Total	60		
Cyclin B	2	34	26.28	893.50
	3	26	36.02	936.50
	Total	60		

<b>Test Statistics<sup>a</sup></b>			
	CDK1	CDK4	Cyclin B
Mann-Whitney U	313.500	403.500	298.500
Wilcoxon W	908.500	998.500	893.500
Z	-1.917	-.574	-2.141
Asymp. Sig. (2-tailed)	.055	.566	.032

### Korelasi antara Cyclin B dan Grade

			Cyclin B	Grade
Spearman's rho	Cyclin B	Correlation Coefficient	1.000	.484**
		Sig. (2-tailed)	.	.000
		N	95	95
	Grade	Correlation Coefficient	.484**	1.000
		Sig. (2-tailed)	.000	.
		N	95	95

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Korelasi antara CDK1 dan Grade

			Grade	CDK1
Spearman's rho	Grade	Correlation Coefficient	1.000	.516**
		Sig. (2-tailed)	.	.000
		N	95	95
	CDK1	Correlation Coefficient	.516**	1.000
		Sig. (2-tailed)	.000	.
		N	95	95

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Korelasi antara CDK4 dan Grade

			Grade	CDK4
Spearman's rho	Grade	Correlation Coefficient	1.000	.348**
		Sig. (2-tailed)	.	.001
		N	95	95
	CDK4	Correlation Coefficient	.348**	1.000
		Sig. (2-tailed)	.001	.
		N	95	95

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Korelasi antara CDK1 dan mitosis

#### Correlations

		CDK1	Mitosis
Spearman's rho	CDK1	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	95
	Mitosis	Correlation Coefficient	.474**
		Sig. (2-tailed)	.000
		N	95

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Korelasi antara CDK4 dan mitosis

#### Correlations

		Mitosis	CDK4
Spearman's rho	Mitosis	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	95
	CDK4	Correlation Coefficient	.384**
		Sig. (2-tailed)	.000
		N	95

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Korelasi antara Cyclin B dan mitosis

#### Correlations

		Mitosis	Cyclin B
Spearman's rho	Mitosis	Correlation Coefficient	1.000
		Sig. (2-tailed)	.
		N	95
	Cyclin B	Correlation Coefficient	.520**
		Sig. (2-tailed)	.000
		N	95

\*\* . Correlation is significant at the 0.01 level (2-tailed).